Free Trial
NASDAQ:PEPG

PepGen (PEPG) Stock Price, News & Analysis

PepGen logo
$1.47 +0.01 (+0.68%)
Closing price 05/27/2025 04:00 PM Eastern
Extended Trading
$1.47 0.00 (0.00%)
As of 05/27/2025 07:44 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About PepGen Stock (NASDAQ:PEPG)

Key Stats

Today's Range
$1.41
$1.50
50-Day Range
$1.00
$1.77
52-Week Range
$0.88
$19.30
Volume
231,432 shs
Average Volume
828,064 shs
Market Capitalization
$48.10 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$9.67
Consensus Rating
Hold

Company Overview

PepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. Its lead product candidate is PGN-EDO51, an EDO peptide that is in Phase 2 clinical trial to treat Duchenne muscular dystrophy (DMD) patients. The company is also developing PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 1 clinical trial for the treatment of myotonic dystrophy type 1, as well as EDO therapeutic candidates, such as PGN-EDO53, PGN-EDO45, and PGN-EDO44 for the treatment of DMD. PepGen Inc. was founded in 2018 and is based in Boston, Massachusetts.

PepGen Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
58th Percentile Overall Score

PEPG MarketRank™: 

PepGen scored higher than 58% of companies evaluated by MarketBeat, and ranked 422nd out of 920 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    PepGen has received a consensus rating of Hold. The company's average rating score is 2.33, and is based on 2 buy ratings, no hold ratings, and 1 sell rating.

  • Amount of Analyst Coverage

    PepGen has only been the subject of 1 research reports in the past 90 days.

  • Read more about PepGen's stock forecast and price target.
  • Earnings Growth

    Earnings for PepGen are expected to grow in the coming year, from ($2.73) to ($2.48) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of PepGen is -0.49, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of PepGen is -0.49, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    PepGen has a P/B Ratio of 0.32. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about PepGen's valuation and earnings.
  • Percentage of Shares Shorted

    8.24% of the float of PepGen has been sold short.
  • Short Interest Ratio / Days to Cover

    PepGen has a short interest ratio ("days to cover") of 0.8, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in PepGen has recently decreased by 18.55%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    PepGen does not currently pay a dividend.

  • Dividend Growth

    PepGen does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    8.24% of the float of PepGen has been sold short.
  • Short Interest Ratio / Days to Cover

    PepGen has a short interest ratio ("days to cover") of 0.8, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in PepGen has recently decreased by 18.55%, indicating that investor sentiment is improving significantly.
  • News Sentiment

    PepGen has a news sentiment score of 0.47. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 1.03 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 3 news articles for PepGen this week, compared to 2 articles on an average week.
  • Insider Buying vs. Insider Selling

    In the past three months, PepGen insiders have bought more of their company's stock than they have sold. Specifically, they have bought $61,225.00 in company stock and sold $0.00 in company stock.

  • Percentage Held by Insiders

    Only 5.20% of the stock of PepGen is held by insiders.

  • Percentage Held by Institutions

    58.01% of the stock of PepGen is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about PepGen's insider trading history.
Receive PEPG Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for PepGen and its competitors with MarketBeat's FREE daily newsletter.

PEPG Stock News Headlines

PepGen Inc.
PepGen appoints new CTO to advance therapies
Man who predicted $100K Bitcoin sees a huge run coming for another coin …
Sure enough, Bitcoin took off on the exact day Juan said it would. It's up more than 40% since the election … surpassing $100,000 on Dec. 8 .… Now Juan believes it could hit $150,000 … or higher in 2025.
PepGen Inc. CEO Makes Bold Stock Purchase!
See More Headlines

PEPG Stock Analysis - Frequently Asked Questions

PepGen's stock was trading at $3.79 at the beginning of 2025. Since then, PEPG shares have decreased by 61.2% and is now trading at $1.47.
View the best growth stocks for 2025 here
.

PepGen Inc. (NASDAQ:PEPG) announced its earnings results on Thursday, May, 8th. The company reported ($0.92) EPS for the quarter, missing analysts' consensus estimates of ($0.72) by $0.20.

PepGen (PEPG) raised $126 million in an initial public offering on Friday, May 6th 2022. The company issued 9,000,000 shares at a price of $13.00-$15.00 per share.

Top institutional shareholders of PepGen include Adage Capital Partners GP L.L.C. (4.13%), Woodline Partners LP (2.39%), Nuveen LLC (0.30%) and AQR Capital Management LLC (0.27%). Insiders that own company stock include Ra Capital Management, LP, James G Mcarthur, Noel Donnelly, Mary Beth Delena, Jaya Goyal, Niels Svenstrup and Michelle L Mellion.
View institutional ownership trends
.

Shares of PEPG stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that PepGen investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), JPMorgan Chase & Co. (JPM), Tesla (TSLA), Meta Platforms (META), Home Depot (HD) and Netflix (NFLX).

Company Calendar

Last Earnings
5/08/2025
Today
5/28/2025
Next Earnings (Estimated)
8/14/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:PEPG
Fax
N/A
Employees
30
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$9.67
High Stock Price Target
$14.00
Low Stock Price Target
$3.00
Potential Upside/Downside
+557.6%
Consensus Rating
Hold
Rating Score (0-4)
2.33
Research Coverage
3 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$78.63 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Book Value
$4.55 per share
Price / Book
0.32

Miscellaneous

Free Float
31,097,000
Market Cap
$48.10 million
Optionable
Not Optionable
Beta
1.39
The Best High-Yield Dividend Stocks for 2025 Cover

Discover the 10 Best High-Yield Dividend Stocks for 2025 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

This page (NASDAQ:PEPG) was last updated on 5/28/2025 by MarketBeat.com Staff
From Our Partners